

ASX ANNOUNCEMENT

5 April 2023

Shareholder update webinar

5 April 2023 – Cann Group Limited (ASX: CAN) (**Cann** or the **Company**) is pleased to invite shareholders, investors and interested parties to an investor update webinar and Q&A with CEO, Peter Koetsier on Monday, 17 April 2023 at 11:00 am (Melbourne time).

After nearly three months in the role of CEO, Peter Koetsier will provide an insight into his views and plans for the Company's strategic direction and commercial activities in FY23 and beyond.

Register for the webinar at the following link:

https://us02web.zoom.us/webinar/register/WN_u5x-WAKvTEucfStRghqbsQ

Shareholders are encouraged to participate in this webinar by submitting questions in advance to:

matt@nwrcommunications.com.au

After registering, you will receive a confirmation email containing information about joining the webinar as well as dial-in details for those that would prefer to join by phone. A recording will be available at the same link used to register for the webinar at the conclusion of the live session.

Authorised for release by Deborah Ambrosini, Company Secretary, Cann Group Limited.

For all information please contact:

Peter Koetsier
CEO
Cann Group Limited
+61 3 9095 7088

contact@canngrouponlimited.com

Deborah Ambrosini
CFO & Company Secretary
Cann Group Limited
+61 3 9095 7088

deborah.ambrosini@canngrouponlimited.com

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is enhancing patients' lives by developing, producing, and supplying innovative cannabis medicines. The Company has built world-class research, cultivation and GMP manufacturing facilities in Melbourne, and a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. Cann Group also owns Satipharm and its patent-protected capsule technology.

Learn more at: www.canngrouponlimited.com | www.satipharm.com